154 results on '"Kushlaf, Hani"'
Search Results
2. Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease
3. Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy.
4. Patient preference for virtual versus in-person visits in neuromuscular clinical practice.
5. Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study.
6. Multiple Sclerosis in a Patient with Friedreich’s Ataxia (P4-6.016)
7. Lack of Relationship Between Myasthenia Gravis and COVID-19 Severity (P4-11.010)
8. Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003)
9. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
10. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
11. Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease
12. Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease
13. Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL
14. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
15. Update on the Diagnostic and Therapeutic Landscape of Sporadic Inclusion Body Myositis
16. P028: Switching treatment to cipaglucosidase alfa+miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease
17. Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial
18. Neurologic and neuroscience education: Mitigating neurophobia to mentor health care providers
19. Genotype-phenotype correlations in valosin-containing protein disease
20. The applicability of the myasthenia gravis patient registry data to disease burden and medication changes in clinical practice
21. Current status of clinical outcome measures in inclusion body myositis: a systematised review
22. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
23. Emerging Toxic Neuropathies and Myopathies
24. The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks
25. Steps in Inclusion Body Myositis
26. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
27. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
28. How does rituximab fit in the treatment algorithm of myasthenia gravis?
29. Extracellular amyloid deposition in sporadic inclusion body myositis: Further insights
30. Proximal median neuropathy caused by surgical manipulation of Masson tumor
31. Training in Neurology: How Lessons Learned on Teaching, Well-being, and Telemedicine During the COVID-19 Pandemic Can Shape the Future of Neurology Education
32. Patient Preference in Virtual Versus In-Person Visits in Neuromuscular Clinical Practice, a Multicenter Survey (1698)
33. Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients (4195)
34. Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy
35. Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients
36. Immune profiling beyond antibodies in double seronegative and acetylcholine receptor antibody positive myasthenia gravis: What do we learn?
37. A rare overlap of statin-induced anti-3-hydroxy-3-methyl-glutaryl-coenzyme A necrotizing autoimmune myositis and dermatomyositis
38. <scp>COVID</scp> ‐19 in muscle‐specific kinase myasthenia gravis: A case report
39. Toxin-Induced Channelopathies, Neuromuscular Junction Disorders, and Myopathy
40. Ultrasound diagnosis of bony nerve entrapment: Case series and literature review
41. CONTRIBUTORS
42. Toxic Myopathies
43. Cystinosis myopathy: Searching for optimal clinical outcome measures
44. COVID ‐19 in muscle‐specific kinase myasthenia gravis: A case report
45. Diving into the Heterogeneity of Inclusion Body Myositis
46. A Novel Myelin Protein Zero variant in Charcot-Marie-Tooth Disease Type 2I (P3.4-038)
47. Peripheral Neuropathy and the Ceruloplasmin Gene
48. The evidence is stacked against thymectomy in MuSK myasthenia gravis
49. New onset of seropositive generalized myasthenia gravis following intravesical bacille Calmette-Guerin treatment for bladder cancer: A case study
50. Botulism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.